CN101048376B - 二氢吲哚化合物及其生产方法 - Google Patents

二氢吲哚化合物及其生产方法 Download PDF

Info

Publication number
CN101048376B
CN101048376B CN2005800370402A CN200580037040A CN101048376B CN 101048376 B CN101048376 B CN 101048376B CN 2005800370402 A CN2005800370402 A CN 2005800370402A CN 200580037040 A CN200580037040 A CN 200580037040A CN 101048376 B CN101048376 B CN 101048376B
Authority
CN
China
Prior art keywords
propyl
dihydro
ethyl
phenoxy
trifluoroethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CN2005800370402A
Other languages
English (en)
Chinese (zh)
Other versions
CN101048376A (zh
Inventor
山口敏章
土屋依久雄
菊池健
柳孝志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of CN101048376A publication Critical patent/CN101048376A/zh
Application granted granted Critical
Publication of CN101048376B publication Critical patent/CN101048376B/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2005800370402A 2004-10-27 2005-10-24 二氢吲哚化合物及其生产方法 Ceased CN101048376B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP313040/2004 2004-10-27
JP2004313040 2004-10-27
PCT/JP2005/019478 WO2006046499A1 (ja) 2004-10-27 2005-10-24 インドリン化合物およびその製造方法

Publications (2)

Publication Number Publication Date
CN101048376A CN101048376A (zh) 2007-10-03
CN101048376B true CN101048376B (zh) 2011-03-23

Family

ID=36227738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800370402A Ceased CN101048376B (zh) 2004-10-27 2005-10-24 二氢吲哚化合物及其生产方法

Country Status (17)

Country Link
US (1) US7834193B2 (enExample)
EP (1) EP1806340B1 (enExample)
JP (1) JP5049013B2 (enExample)
KR (1) KR101249865B1 (enExample)
CN (1) CN101048376B (enExample)
AT (1) ATE508113T1 (enExample)
AU (1) AU2005298078B2 (enExample)
BR (1) BRPI0517515B8 (enExample)
CA (1) CA2583660C (enExample)
DE (1) DE602005027881D1 (enExample)
ES (1) ES2362788T3 (enExample)
IL (1) IL182642A (enExample)
MX (1) MX2007005126A (enExample)
RU (1) RU2379289C2 (enExample)
TW (1) TW200621709A (enExample)
WO (1) WO2006046499A1 (enExample)
ZA (1) ZA200703996B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
US8013007B2 (en) 2007-02-26 2011-09-06 Concert Pharmaceuticals, Inc. Alpha 1A-adrenoceptor antagonists
US20080242717A1 (en) * 2007-02-28 2008-10-02 Fumiyasu Sato Methods for treating benign prostatic hyperplasia
CN101585798B (zh) * 2008-05-20 2011-06-15 浙江华海药业股份有限公司 光学活性化合物1-(3-苯甲酰氧基丙基)-5-(2-(1-苯基乙基胺)丙基)-7-氰基吲哚啉及其制备方法和用途
CN101993406B (zh) * 2009-08-27 2014-01-15 浙江华海药业股份有限公司 光学活性的吲哚啉化合物及其制备方法
CN101993407B (zh) * 2009-08-27 2014-01-29 浙江华海药业股份有限公司 用于制备西洛多辛的吲哚啉化合物及其制备方法
CN101993405B (zh) * 2009-08-27 2014-01-15 浙江华海药业股份有限公司 吲哚啉衍生物、及其制备方法和用途
WO2011030356A2 (en) 2009-09-12 2011-03-17 Sandoz Ag Process for the preparation of indoline derivatives and their intermediates thereof
CN101768056B (zh) * 2010-01-19 2013-10-16 扬子江药业集团有限公司 一种取代的苯基甲基醚的制备方法
WO2011101864A1 (en) 2010-02-17 2011-08-25 Panacea Biotec Ltd Novel process for the synthesis of phenoxyethyl derivatives
WO2011124704A1 (en) 2010-04-09 2011-10-13 Ratiopharm Gmbh Process for preparing an intermediate for silodosin
CN102311319A (zh) * 2010-07-05 2012-01-11 浙江华海药业股份有限公司 一种制备2-(2,2,2-三氟乙基)苯甲醚的方法
WO2012014186A1 (en) * 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Process for the preparation of silodosin and its novel intermediates
CN102229558B (zh) * 2010-08-05 2013-05-08 南京海纳医药科技有限公司 西洛多辛的晶型δ、它的制备方法和包含它的药物组合物
CN102229557B (zh) * 2010-08-05 2013-03-27 南京海纳医药科技有限公司 西洛多辛的半水合物晶体、制备方法和包含它的药物组合物
CZ303061B6 (cs) * 2010-11-12 2012-03-14 Zentiva, K.S. Zpusob výroby (-)-1-(3-hydroxypropyl)-5-[(2R)-2-({2,2,2-trifluorethoxy)fenoxyethyl}amino)propyl]-2,3-dihydro-1H-indol-7-karboxamidu
WO2012062229A1 (en) 2010-11-12 2012-05-18 Zentiva, K.S. A method of manufacturing (-)-l-(3-hydroxypropyl)-5-[(2r)-2-({2,2,2-trifluoroethoxy)- phenoxyethyl}amino)propyl]-2,3-dihydro-lh-indole-7-carboxamide
CZ2010836A3 (cs) * 2010-11-12 2012-03-14 Zentiva, K.S. Zpusob výroby (-)-1-(3-hydroxypropyl)-5-[(2R)-2-({2,2,2-trifluorethoxy)fenoxyethyl}amino)propyl]-2,3-dihydro-1H-indol-7-karboxamidu
WO2012131710A2 (en) 2011-03-30 2012-10-04 Panacea Biotec Ltd Novel process for the synthesis of indoline derivatives
WO2012147019A1 (en) * 2011-04-26 2012-11-01 Orchid Chemicals And Pharamceuticals Limited An improved process for the preparation of silodosin
WO2012147107A2 (en) * 2011-04-29 2012-11-01 Msn Laboratories Limited Novel & improved processes for the preparation of indoline derivatives and its pharmaceutical composition
CN102382029B (zh) * 2011-07-26 2016-06-29 浙江华海药业股份有限公司 一种西洛多辛中间体成盐制备方法
WO2013072935A2 (en) 2011-10-10 2013-05-23 Cadila Healthcare Limited Process for the preparation of silodosin
IN2014KN01030A (enExample) 2011-10-21 2015-10-09 Sandoz Ag
CN102675182B (zh) * 2012-05-24 2014-03-26 临海天宇药业有限公司 1-(3-苯甲酰氧基丙基)-5-(2-羰基丙基)-7-腈基吲哚啉的制备方法
WO2014118606A2 (en) * 2013-01-29 2014-08-07 Alembic Pharmaceuticals Limited A novel process for the preparation of silodosin
CN103159664B (zh) * 2013-03-29 2016-03-23 深圳市海滨制药有限公司 一种赛洛多辛原料药及其制备方法、药物组合物
CN104140389A (zh) * 2013-05-06 2014-11-12 昆明积大制药股份有限公司 一种赛洛多辛及其中间体的制备方法
CN103420893B (zh) * 2013-08-02 2015-11-25 江苏和成新材料有限公司 制备西洛多辛中间体的方法
JP6225998B2 (ja) * 2014-02-06 2017-11-08 宇部興産株式会社 インドリン化合物の製造方法
KR20150098565A (ko) * 2014-02-20 2015-08-28 한미정밀화학주식회사 실로도신 제조에 사용되는 신규 중간체, 이의 제조방법 및 이를 이용한 실로도신의 제조방법
KR20150127996A (ko) * 2014-05-08 2015-11-18 한미정밀화학주식회사 실로도신 감마형 결정의 제조방법
JP6242298B2 (ja) * 2014-06-13 2017-12-06 株式会社トクヤマ １−（３−ベンゾイルオキシプロピル）−７−シアノ−５−［（２ｒ）−２−（｛２−［２−（２，２，２−トリフルオロエトキシ）フェノキシ］エチル｝アミノ）プロピル］インドリンまたはその塩を製造する方法
KR101628946B1 (ko) * 2014-07-09 2016-06-09 동방에프티엘(주) 실로도신의 개선된 제조방법
KR101725393B1 (ko) * 2014-07-24 2017-04-27 주식회사 경보제약 실로도신의 제조 방법 및 신규 중간체
WO2016042441A1 (en) 2014-09-18 2016-03-24 Mankind Research Centre A novel process for the preparation of considerably pure silodosin
JP2016088847A (ja) * 2014-10-30 2016-05-23 株式会社トクヤマ （‐）‐１‐（３‐ヒドロキシプロピル）‐５‐［［（２ｒ）‐２‐（｛２‐［２‐（２，２，２‐トリフルオロエトキシ）フェノキシ］エチル｝アミノ）プロピル］‐２，３‐ジヒドロ‐１ｈ‐インドール‐７‐カルボキサミド］）の製造方法
CN104478784B (zh) * 2014-11-17 2017-02-22 武汉工程大学 一种西洛多辛草酸盐的晶型及其制备方法
KR101694262B1 (ko) * 2014-12-18 2017-01-10 (주)다산메디켐 실로도신의 결정형의 제조방법
US9356405B1 (en) 2015-03-05 2016-05-31 Sony Corporation Connector tongue element for an electrical connector plug receptacle and a method for producing the same
BR112018005934A2 (pt) 2015-09-23 2018-10-09 Biocon Ltd formas cristalinas de intermediário de posaconazol e processo para a preparação de posaconazol amorfo
RU2018114512A (ru) * 2015-09-23 2019-10-23 Биокон Лимитед Способ получения соединений индолина и новая соль индолина
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
CN106995399A (zh) * 2016-01-25 2017-08-01 北京天泰恒华医药技术有限公司 一种制备赛洛多辛的方法
KR102365411B1 (ko) * 2017-08-08 2022-02-21 (주)헥사파마텍 신규의 설폰아마이드 중간체 및 이를 사용한 실로도신의 제조방법
KR102163068B1 (ko) * 2018-07-04 2020-10-07 주식회사 가피바이오 실로도신 합성용 중간체의 제조 방법 및 이를 이용한 실로도신의 제조 방법
CN111217735B (zh) * 2018-11-27 2023-03-14 上海汇伦医药股份有限公司 赛洛多辛中间体的制备方法
WO2020237645A1 (zh) * 2019-05-31 2020-12-03 上海汇伦生命科技有限公司 赛洛多辛中间体的制备方法
CN110452149B (zh) * 2019-06-13 2021-11-02 北京鑫开元医药科技有限公司 二氢吲哚化合物的制备方法、二氢吲哚化合物及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001199956A (ja) * 2000-01-14 2001-07-24 Kissei Pharmaceut Co Ltd 光学活性なインドリン誘導体の製造方法およびその製造中間体
JP2002265444A (ja) * 2001-03-08 2002-09-18 Kissei Pharmaceut Co Ltd １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679903B1 (fr) * 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
DE122010000031I1 (de) * 1992-12-02 2010-10-21 Kissei Pharmaceutical Indolin Verbindungen zur Behandlung von Dysurien
TW281669B (enExample) * 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
JP3331047B2 (ja) * 1994-06-01 2002-10-07 キッセイ薬品工業株式会社 インドリン誘導体
JP2526811B2 (ja) * 1994-07-22 1996-08-21 田辺製薬株式会社 フェネチルアミン誘導体及びその製法
BR9908301A (pt) * 1998-02-27 2000-10-31 Kissei Pharmaceutical Derivados de indol e composições farmacêuticas que compreendem os mesmos
JP2006188470A (ja) * 2005-01-07 2006-07-20 Kissei Pharmaceut Co Ltd インドリン誘導体およびその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001199956A (ja) * 2000-01-14 2001-07-24 Kissei Pharmaceut Co Ltd 光学活性なインドリン誘導体の製造方法およびその製造中間体
JP2002265444A (ja) * 2001-03-08 2002-09-18 Kissei Pharmaceut Co Ltd １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法

Also Published As

Publication number Publication date
IL182642A0 (en) 2007-07-24
DE602005027881D1 (de) 2011-06-16
IL182642A (en) 2012-10-31
US20070197627A1 (en) 2007-08-23
CA2583660A1 (en) 2006-05-04
ATE508113T1 (de) 2011-05-15
ZA200703996B (en) 2008-09-25
ES2362788T3 (es) 2011-07-13
WO2006046499A1 (ja) 2006-05-04
EP1806340A4 (en) 2009-08-12
TW200621709A (en) 2006-07-01
AU2005298078B2 (en) 2011-03-31
KR20070084499A (ko) 2007-08-24
TWI356819B (enExample) 2012-01-21
JP5049013B2 (ja) 2012-10-17
BRPI0517515B1 (pt) 2021-03-09
BRPI0517515A (pt) 2008-10-14
KR101249865B1 (ko) 2013-04-02
CN101048376A (zh) 2007-10-03
RU2007115888A (ru) 2008-11-10
CA2583660C (en) 2013-02-12
JPWO2006046499A1 (ja) 2008-05-22
HK1113364A1 (en) 2008-10-03
EP1806340A1 (en) 2007-07-11
AU2005298078A1 (en) 2006-05-04
US7834193B2 (en) 2010-11-16
EP1806340B1 (en) 2011-05-04
MX2007005126A (es) 2007-07-04
BRPI0517515B8 (pt) 2021-05-25
RU2379289C2 (ru) 2010-01-20

Similar Documents

Publication Publication Date Title
CN101048376B (zh) 二氢吲哚化合物及其生产方法
US12221417B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
WO2016180033A1 (zh) 一种前列环素受体激动剂的制备方法
US20140179922A1 (en) Intermediate compounds and process for the preparation of lurasidone and salts thereof
JP2019523273A (ja) ベリノスタットの多形形態、およびその調製のためのプロセス
JP7036724B2 (ja) ピラゾール－アミド化合物の製造方法
JP2018516912A (ja) アプレミラストおよびその新規な多形の改善された製造方法
TW200831090A (en) Factor Xa inhibitor
US20180339964A1 (en) The process of preparing indoline compounds and a novel indolinesalt
JP2009035513A (ja) ４−ｎ−（メチルベンゾイル）アミノ−２−メチル安息香酸の製法
JP2007517797A (ja) 高化学的ｒ−５−（２−（２−エトキシフェノキシエチルアミノ）プロピル）−２−メトキシベンゼンスルホンアミド塩酸塩の調製
HK1113364B (en) Indoline compound and process for producing the same
JP4424728B2 (ja) 置換フェニルプロピオン酸誘導体の新規な安定結晶とその製法
EP1566381B1 (en) Process for production of 1- 2-(benzimidazol-2-yl- thio)ethyl piperazine or salts thereof
JP2005220079A (ja) ピロリジン化合物の合成とその結晶
CN120535447A (zh) 一种二酰基吡咯类组蛋白去乙酰化酶6抑制剂及其用途
JPH07215968A (ja) アゼラスチンの製造方法
JP2007230906A (ja) Ｎ，ｎ−ジメチルカルバモイルメチル４‐ヒドロキシフェニルアセテートの製造法
WO2004113321A1 (ja) 選択的なアミノ置換基導入法
JP2007513943A (ja) 光学的に純粋なフェネチルアミン誘導体の調製方法
CA2439208A1 (en) Process for producing optically active n-aryl-1-amino-2-propanol derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1113364

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1113364

Country of ref document: HK

IW01 Full invalidation of patent right
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20240607

Decision number of declaring invalidation: 568495

Granted publication date: 20110323